vs
American Water Works（AWK）与豪洛捷（HOLX）财务数据对比。点击上方公司名可切换其他公司
American Water Works的季度营收约是豪洛捷的1.2倍（$1.3B vs $1.0B），American Water Works净利率更高（18.7% vs 17.1%，领先1.6%），American Water Works同比增速更快（5.8% vs 2.5%），豪洛捷自由现金流更多（$215.2M vs $-385.0M），过去两年American Water Works的营收复合增速更高（12.6% vs 1.5%）
American Water Works通过旗下子公司在美国境内提供专业供水与污水处理服务，业务覆盖14个州的约1700个社区，服务约340万活跃用户，客户群体涵盖住宅用户、食品饮料供应商、商业地产开发商与运营商、能源供应商等商业客户、消防服务及工业类客户等。
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
AWK vs HOLX — 直观对比
营收规模更大
AWK
是对方的1.2倍
$1.0B
营收增速更快
AWK
高出3.3%
2.5%
净利率更高
AWK
高出1.6%
17.1%
自由现金流更多
HOLX
多$600.2M
$-385.0M
两年增速更快
AWK
近两年复合增速
1.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.0B |
| 净利润 | $238.0M | $179.1M |
| 毛利率 | — | 56.0% |
| 营业利润率 | 31.9% | 22.6% |
| 净利率 | 18.7% | 17.1% |
| 营收同比 | 5.8% | 2.5% |
| 净利润同比 | -0.4% | -10.9% |
| 每股收益（稀释后） | $1.22 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AWKHOLX
| Q4 25 | $1.3B | $1.0B | ||
| Q3 25 | $1.5B | $1.0B | ||
| Q2 25 | $1.3B | $1.0B | ||
| Q1 25 | $1.1B | $1.0B | ||
| Q4 24 | $1.2B | $1.0B | ||
| Q3 24 | $1.3B | $988.0M | ||
| Q2 24 | $1.1B | $1.0B | ||
| Q1 24 | $1.0B | $1.0B |
净利润AWKHOLX
| Q4 25 | $238.0M | $179.1M | ||
| Q3 25 | $379.0M | $187.2M | ||
| Q2 25 | $289.0M | $194.9M | ||
| Q1 25 | $205.0M | $-17.4M | ||
| Q4 24 | $239.0M | $201.0M | ||
| Q3 24 | $350.0M | $178.6M | ||
| Q2 24 | $277.0M | $194.5M | ||
| Q1 24 | $185.0M | $169.9M |
毛利率AWKHOLX
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% | ||
| Q1 24 | — | 53.3% |
营业利润率AWKHOLX
| Q4 25 | 31.9% | 22.6% | ||
| Q3 25 | 42.2% | 22.6% | ||
| Q2 25 | 38.4% | 24.9% | ||
| Q1 25 | 32.7% | -0.7% | ||
| Q4 24 | 33.3% | 22.5% | ||
| Q3 24 | 40.9% | 23.3% | ||
| Q2 24 | 39.4% | 24.1% | ||
| Q1 24 | 32.5% | 20.7% |
净利率AWKHOLX
| Q4 25 | 18.7% | 17.1% | ||
| Q3 25 | 26.1% | 17.8% | ||
| Q2 25 | 22.7% | 19.0% | ||
| Q1 25 | 18.1% | -1.7% | ||
| Q4 24 | 19.9% | 19.7% | ||
| Q3 24 | 26.4% | 18.1% | ||
| Q2 24 | 24.3% | 19.2% | ||
| Q1 24 | 18.4% | 16.7% |
每股收益（稀释后）AWKHOLX
| Q4 25 | $1.22 | $0.79 | ||
| Q3 25 | $1.94 | $0.84 | ||
| Q2 25 | $1.48 | $0.86 | ||
| Q1 25 | $1.05 | $-0.08 | ||
| Q4 24 | $1.22 | $0.87 | ||
| Q3 24 | $1.80 | $0.75 | ||
| Q2 24 | $1.42 | $0.82 | ||
| Q1 24 | $0.95 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.0M | $2.4B |
| 总债务越低越好 | $12.8B | $2.5B |
| 股东权益账面价值 | $10.8B | $5.2B |
| 总资产 | $35.4B | $9.2B |
| 负债/权益比越低杠杆越低 | 1.18× | 0.48× |
8季度趋势，按日历期对齐
现金及短期投资AWKHOLX
| Q4 25 | $98.0M | $2.4B | ||
| Q3 25 | $166.0M | $2.2B | ||
| Q2 25 | $94.0M | $1.9B | ||
| Q1 25 | $114.0M | $1.6B | ||
| Q4 24 | $96.0M | $2.0B | ||
| Q3 24 | $127.0M | $2.3B | ||
| Q2 24 | $48.0M | $2.4B | ||
| Q1 24 | $584.0M | $2.2B |
总债务AWKHOLX
| Q4 25 | $12.8B | $2.5B | ||
| Q3 25 | $13.0B | $2.5B | ||
| Q2 25 | $12.3B | $2.5B | ||
| Q1 25 | $13.3B | $2.5B | ||
| Q4 24 | $12.5B | $2.5B | ||
| Q3 24 | $12.6B | $2.5B | ||
| Q2 24 | $12.6B | $2.5B | ||
| Q1 24 | $12.6B | $2.6B |
股东权益AWKHOLX
| Q4 25 | $10.8B | $5.2B | ||
| Q3 25 | $10.9B | $5.0B | ||
| Q2 25 | $10.7B | $4.8B | ||
| Q1 25 | $10.5B | $4.6B | ||
| Q4 24 | $10.3B | $4.8B | ||
| Q3 24 | $10.4B | $5.1B | ||
| Q2 24 | $10.2B | $5.0B | ||
| Q1 24 | $10.0B | $4.8B |
总资产AWKHOLX
| Q4 25 | $35.4B | $9.2B | ||
| Q3 25 | $34.7B | $9.0B | ||
| Q2 25 | $33.9B | $8.8B | ||
| Q1 25 | $33.2B | $8.5B | ||
| Q4 24 | $32.8B | $8.7B | ||
| Q3 24 | $31.8B | $9.2B | ||
| Q2 24 | $31.2B | $8.9B | ||
| Q1 24 | $31.1B | $8.7B |
负债/权益比AWKHOLX
| Q4 25 | 1.18× | 0.48× | ||
| Q3 25 | 1.19× | 0.50× | ||
| Q2 25 | 1.15× | 0.52× | ||
| Q1 25 | 1.26× | 0.55× | ||
| Q4 24 | 1.21× | 0.53× | ||
| Q3 24 | 1.21× | 0.49× | ||
| Q2 24 | 1.24× | 0.51× | ||
| Q1 24 | 1.26× | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $663.0M | $229.9M |
| 自由现金流经营现金流 - 资本支出 | $-385.0M | $215.2M |
| 自由现金流率自由现金流/营收 | -30.3% | 20.5% |
| 资本支出强度资本支出/营收 | 82.5% | 1.4% |
| 现金转化率经营现金流/净利润 | 2.79× | 1.28× |
| 过去12个月自由现金流最近4个季度 | $-1.1B | $1.0B |
8季度趋势，按日历期对齐
经营现金流AWKHOLX
| Q4 25 | $663.0M | $229.9M | ||
| Q3 25 | $764.0M | $355.1M | ||
| Q2 25 | $301.0M | $343.3M | ||
| Q1 25 | $331.0M | $169.4M | ||
| Q4 24 | $639.0M | $189.3M | ||
| Q3 24 | $679.0M | $367.0M | ||
| Q2 24 | $345.0M | $405.8M | ||
| Q1 24 | $382.0M | $292.4M |
自由现金流AWKHOLX
| Q4 25 | $-385.0M | $215.2M | ||
| Q3 25 | $-33.0M | $341.4M | ||
| Q2 25 | $-432.0M | $330.5M | ||
| Q1 25 | $-217.0M | $153.9M | ||
| Q4 24 | $-255.0M | $172.5M | ||
| Q3 24 | $-4.0M | $350.6M | ||
| Q2 24 | $-325.0M | $385.3M | ||
| Q1 24 | $-227.0M | $279.6M |
自由现金流率AWKHOLX
| Q4 25 | -30.3% | 20.5% | ||
| Q3 25 | -2.3% | 32.5% | ||
| Q2 25 | -34.0% | 32.3% | ||
| Q1 25 | -19.1% | 15.3% | ||
| Q4 24 | -21.2% | 16.9% | ||
| Q3 24 | -0.3% | 35.5% | ||
| Q2 24 | -28.5% | 38.1% | ||
| Q1 24 | -22.6% | 27.5% |
资本支出强度AWKHOLX
| Q4 25 | 82.5% | 1.4% | ||
| Q3 25 | 54.8% | 1.3% | ||
| Q2 25 | 57.6% | 1.3% | ||
| Q1 25 | 48.3% | 1.5% | ||
| Q4 24 | 74.4% | 1.6% | ||
| Q3 24 | 51.4% | 1.7% | ||
| Q2 24 | 58.8% | 2.0% | ||
| Q1 24 | 60.7% | 1.3% |
现金转化率AWKHOLX
| Q4 25 | 2.79× | 1.28× | ||
| Q3 25 | 2.02× | 1.90× | ||
| Q2 25 | 1.04× | 1.76× | ||
| Q1 25 | 1.61× | — | ||
| Q4 24 | 2.67× | 0.94× | ||
| Q3 24 | 1.94× | 2.05× | ||
| Q2 24 | 1.25× | 2.09× | ||
| Q1 24 | 2.06× | 1.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AWK
| Water Services | $1.0B | 81% |
| Other | $127.0M | 10% |
| Wastewater Services | $101.0M | 8% |
| Miscellaneous Utility Charge | $11.0M | 1% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
